The Europe Smart Inhalers Market would witness market growth of 24.0% CAGR during the forecast period (2021-2027).
The devices that have been created so far appear to function with a wide range of inhalers. it is known that individuals with asthma may need to move between inhalers, therefore it's critical that as these are launched, people with asthma can effortlessly switch between treatments while still using a smart inhaler. Bluetooth is used to connect the devices to cell phones. Each manufacturer typically has a smartphone app that allows the user to view their data or adjust their reminder settings, although these apps may not be accessible for all smartphone models. So far, the smart inhaler apps that have surfaced appear to function on both iPhone and Android devices.
Digital medicines are the wave of the future, allowing for even more personalization of chronic illness management as well as unmatched patient health and treatment adherence monitoring. Patients with asthma or COPD can use digital inhalers to gain more control over their condition, identify triggers, connect and share information with their doctors, and collect valuable research data. By establishing pertinent alerts or notifications, the technology is a great tool for facilitating adherence to treatment schedules, dosage reminders, and tracking inhaler usage. Some digital inhalers may even detect and alarm patients if they fail to carry their gadgets with them or track excessive levels of pollution or pollen
The expansion of the smart inhalers market in Europe is attributed to the increased acceptance of smart inhalation devices and increasing demands for digital medical devices in Germany, the United Kingdom, and France, owing to a need to improve the patient experience. The presence of significant suppliers operating in the European market also contributes to the high growth rate.
Asthma impacted over 6% of the EU population in 2019, a minor rise from 2014 (+0.3%). Finland topped the list among EU countries, with 9% of the population reporting asthma, followed by Germany and France (both 8%). In Romania and Bulgaria, however, only 2% of the population reported having this condition. In 2019, the number of people reporting asthma increased the highest in Germany (+1.9%), Croatia (+1.8%), and Belgium (+1.5%) compared to 2014. On the other hand, Ireland (-1.7%), Greece (-1.1%), and France (1.0 percentage point) saw the greatest decline in the number of patients reporting this disease.
The Germany market dominated the Europe Smart Inhalers Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $27,184 Thousands by 2027. The UK market is experiencing a CAGR of 23.1% during (2021 - 2027). Additionally, The France market would witness a CAGR of 25% during (2021 - 2027).
Based on Product, the market is segmented into Metered Dose Inhalers (MDI's), and Dry Powdered Inhalers (DPIs). Based on Disease Indication, the market is segmented into Asthma, and Chronic Obstructive Pulmonary Disease (COPD). Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Smart Inhalers Market Size will Hit $414.4 Million by 2027, at a CAGR of 24.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Adherium Limited, Aptar Group Inc. (Cohero Health Inc.), AstraZeneca, Inc., Cognita Labs, LLC, GlaxoSmithKline Plc, Novartis AG, OPKO Health, Inc., Philip Morris International, Inc. (Vectura Group Plc), Resmed, Inc. (Propeller Health), and Teva Pharmaceutical Industries Ltd.
By Product
By Disease Indication
By Distribution Channel
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
